Akorn Recalls Hydrocortisone and Acetic Acid Otic Solution Due to Low Potency
Akorn Inc is recalling Hydrocortisone and Acetic Acid Otic Solution because routine stability testing revealed the drug was sub-potent.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which is reasonably likely to cause temporary or medically reversible health consequences. The hazard is sub-potency, which is a lower risk than contamination or serious injury, fitting the Moderate category.
Plain-English summary
Akorn Inc is recalling Hydrocortisone and Acetic Acid Otic Solution, USP, 10 mL per dropper bottle. The recall involves 15,322 bottles of the prescription medication, identified by Lot 357647 and an expiration date of 04/2019. The product was distributed nationwide in the United States and Puerto Rico.
The recall was initiated because routine stability testing at 12 months under controlled room temperature conditions showed out-of-specification results for the Hydrocortisone assay. This indicates the medication was sub-potent, meaning it contained less of the active ingredient than required.
Consumers and healthcare providers should stop using the recalled product and return it to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- Hydrocortisone and Acetic Acid Otic Solution, USP, 10 mL per dropper bottle, Rx only, Hi-Tech Pharmacal Co, Inc., Amityville, NY 11701. NDC: 50383-901-10
- Manufacturer
- Akorn Inc
- Category
- Drug — Ophthalmic/Ear Drops
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: 357647
- EXP 04/2019
Distribution
Related recalls
Same manufacturer · Akorn Inc
See all →- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · sub potency
See all →- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- HighLorazepam Tablets Recalled for Failed Impurity and Potency Specifications
FDA (Drugs) · 2025-02-26
- HighLorazepam tablets recalled due to failed potency and impurity specifications
FDA (Drugs) · 2025-02-26
- LowSinuFrin Nasal Decongestant Recalled for Sub-Potency Nationwide
FDA (Drugs) · 2024-07-03
- SevereSapropterin Dihydrochloride Powder for Oral Solution Recalled Due to Sub-Potency
FDA (Drugs) · 2024-05-15